ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
$9.01 -0.69 (-7.11%)
As of 02/08/2023 15:59:55 EST IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Canada
Country of incorporation: Canada
IPO date: 04/28/2017
Outstanding shares: 63,003,370
Average volume: 1,035,350
Market cap: $618,693,093
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%